ES2368996T3 - Derivados de pirimidinas inhibidores del hiv - Google Patents

Derivados de pirimidinas inhibidores del hiv Download PDF

Info

Publication number
ES2368996T3
ES2368996T3 ES02764839T ES02764839T ES2368996T3 ES 2368996 T3 ES2368996 T3 ES 2368996T3 ES 02764839 T ES02764839 T ES 02764839T ES 02764839 T ES02764839 T ES 02764839T ES 2368996 T3 ES2368996 T3 ES 2368996T3
Authority
ES
Spain
Prior art keywords
compound
amino
compound according
pharmaceutically acceptable
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02764839T
Other languages
English (en)
Spanish (es)
Inventor
Jérôme Emile Georges GUILLEMONT
Patrice Palandjian
Marc René de Jonge
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Frederik Frans Desiré Daeyaert
Jan Heeres
Koen Jeanne Alfons Van Aken
Paulus Joannes Lewi
Paul Adriaan Jan Janssen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2368996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2368996T3 publication Critical patent/ES2368996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES02764839T 2001-08-13 2002-08-09 Derivados de pirimidinas inhibidores del hiv Expired - Lifetime ES2368996T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01203090 2001-08-13
EP01203090 2001-08-13
EP02077748 2002-06-10
EP02077748 2002-06-10
PCT/EP2002/008953 WO2003016306A1 (en) 2001-08-13 2002-08-09 Hiv inhibiting pyrimidines derivatives

Publications (1)

Publication Number Publication Date
ES2368996T3 true ES2368996T3 (es) 2011-11-24

Family

ID=26076978

Family Applications (3)

Application Number Title Priority Date Filing Date
ES02764839T Expired - Lifetime ES2368996T3 (es) 2001-08-13 2002-08-09 Derivados de pirimidinas inhibidores del hiv
ES10178189T Expired - Lifetime ES2799408T3 (es) 2001-08-13 2002-08-09 Derivados de pirimidina inhibidores del VIH
ES20165399T Expired - Lifetime ES2923581T3 (es) 2001-08-13 2002-08-09 Pirimidinas inhibidoras de la replicación del VIH

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10178189T Expired - Lifetime ES2799408T3 (es) 2001-08-13 2002-08-09 Derivados de pirimidina inhibidores del VIH
ES20165399T Expired - Lifetime ES2923581T3 (es) 2001-08-13 2002-08-09 Pirimidinas inhibidoras de la replicación del VIH

Country Status (37)

Country Link
US (8) US7125879B2 (OSRAM)
EP (3) EP1419152B1 (OSRAM)
JP (4) JP2005507380A (OSRAM)
KR (2) KR100969273B1 (OSRAM)
CN (2) CN101816658B (OSRAM)
AP (1) AP1610A (OSRAM)
AR (1) AR036387A1 (OSRAM)
AT (1) ATE517891T1 (OSRAM)
AU (1) AU2002329238C1 (OSRAM)
BE (3) BE2012C020I2 (OSRAM)
BR (3) BR122015032641B1 (OSRAM)
CA (1) CA2452217C (OSRAM)
CY (4) CY1112331T1 (OSRAM)
DE (1) DE122012000038I1 (OSRAM)
DK (2) DK1419152T3 (OSRAM)
EA (1) EA006656B1 (OSRAM)
EG (1) EG24684A (OSRAM)
ES (3) ES2368996T3 (OSRAM)
FR (3) FR12C0035I2 (OSRAM)
HR (3) HRP20040096B1 (OSRAM)
HU (5) HU231274B1 (OSRAM)
IL (2) IL160328A0 (OSRAM)
JO (1) JO3429B1 (OSRAM)
LT (3) LT3808743T (OSRAM)
LU (2) LU92001I2 (OSRAM)
MX (1) MXPA04001401A (OSRAM)
MY (1) MY189572A (OSRAM)
NO (3) NO327639B1 (OSRAM)
NZ (1) NZ530951A (OSRAM)
OA (1) OA12652A (OSRAM)
PA (1) PA8552901A1 (OSRAM)
PL (2) PL402388A1 (OSRAM)
PT (1) PT1419152E (OSRAM)
SI (2) SI1419152T1 (OSRAM)
UA (1) UA78221C2 (OSRAM)
WO (1) WO2003016306A1 (OSRAM)
ZA (1) ZA200401159B (OSRAM)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ES2311146T3 (es) * 2003-02-07 2009-02-01 Janssen Pharmaceutica Nv 1,2,4-triazinas que inhiben el vih.
CN1747937A (zh) * 2003-02-07 2006-03-15 詹森药业有限公司 预防hiv感染的嘧啶衍生物
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2005011702A1 (en) 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
PL2287156T3 (pl) * 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
TWI365744B (en) * 2003-09-03 2012-06-11 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
BRPI0414791A (pt) 2003-09-25 2006-11-21 Janssen Pharmaceutica Nv derivados de purina inibidores da replicação do hiv
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
ES2442857T3 (es) 2004-08-10 2014-02-13 Janssen Pharmaceutica Nv Derivados de 1,2,4-triazin-6-ona inhibidores de VIH
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
AP2487A (en) * 2004-09-02 2012-10-03 Janssen Pharmaceutica Nv Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
MX2007002595A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AP2296A (en) * 2004-09-02 2011-10-31 Janssen Pharmaceutica Nv Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515935B8 (pt) * 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica
WO2006035069A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
WO2006035067A2 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7906511B2 (en) 2005-03-31 2011-03-15 Santen Pharmaceutical Co., Ltd. Cyclic compound having pyrimidinylalkylthio group
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
ES2380951T3 (es) 2005-05-05 2012-05-21 Ardea Biosciences, Inc. Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
DK1888537T3 (da) * 2005-05-26 2013-12-09 Janssen R & D Ireland Fremgangsmåde til fremstilling af 4[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitril
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ME01617B (me) 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
DK2004641T3 (da) 2006-03-30 2011-01-24 Tibotec Pharm Ltd HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
SG173315A1 (en) 2006-06-23 2011-08-29 Tibotec Pharm Ltd Aqueous suspensions of tmc278
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
US7595324B2 (en) 2006-11-09 2009-09-29 Ardea Biosciences, Inc. Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2469032C2 (ru) * 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
EA020749B1 (ru) 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
AU2008257771B2 (en) 2007-05-30 2015-02-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
SI2175857T1 (sl) * 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
CN101407476B (zh) * 2007-10-12 2012-07-18 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
MX2010005776A (es) 2007-11-27 2010-08-31 Ardea Biosciences Inc Nuevos compuestos y composiciones y metodos de uso.
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
KR20110039563A (ko) 2008-07-23 2011-04-19 버텍스 파마슈티칼스 인코포레이티드 피라졸로피리딘 키나제 억제제
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP2011530527A (ja) 2008-08-06 2011-12-22 バーテックス ファーマシューティカルズ インコーポレイテッド アミノピリジンキナーゼ阻害剤
CN101717364B (zh) * 2008-10-09 2014-08-13 中国人民解放军军事医学科学院毒物药物研究所 作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
EP2351739B1 (en) 2008-10-09 2013-07-31 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
JP5612602B2 (ja) 2008-12-24 2014-10-22 ヤンセン・アールアンドデイ・アイルランド Ｈｉｖ処置用の移植可能デバイス
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
WO2011094290A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
MX2012008641A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopirazinas.
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジンキナーゼ阻害剤
PT3494972T (pt) 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
EP2536696A1 (en) * 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US8367315B2 (en) 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
ES2617763T3 (es) 2010-08-10 2017-06-19 Celgene Avilomics Research, Inc. Sal de besilato de un inhibidor de BTK
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
CA2818097C (en) 2010-11-19 2019-07-30 Janssen R & D Ireland Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
MY166890A (en) 2011-08-30 2018-07-24 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2848631C (en) * 2011-09-16 2019-10-01 Hetero Research Foundation Rilpivirine hydrochloride
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
ES2664094T3 (es) * 2012-07-12 2018-04-18 Hetero Research Foundation Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP2017520610A (ja) * 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ｈｉｖ関連障害を治療するための方法及び組成物
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
MX2017003928A (es) 2014-09-26 2017-06-28 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada.
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
PE20180411A1 (es) 2015-06-30 2018-03-01 Gilead Sciences Inc Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) * 2016-07-04 2018-08-21 宜昌人福药业有限责任公司 一种有效去除利匹韦林异构体的方法
KR20190073450A (ko) 2016-10-24 2019-06-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 분산성 조성물
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) * 2016-12-08 2018-12-25 西北师范大学 一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) * 2017-02-27 2019-08-16 武汉工程大学 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
EP3645003A4 (en) 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
EP3853234B1 (en) 2018-09-18 2025-04-23 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN109293581B (zh) * 2018-09-21 2020-03-27 宜昌人福药业有限责任公司 一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CA3144534A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
WO2022000019A1 (en) * 2020-06-30 2022-01-06 University Of South Australia New therapeutic use of rilpivirine
CN112028836B (zh) * 2020-09-09 2021-12-07 山东大学 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) * 2021-03-08 2021-07-13 复旦大学 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) * 2021-05-06 2021-10-01 复旦大学 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) * 2021-09-03 2021-12-28 复旦大学 一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
MX2024006005A (es) 2021-11-17 2024-05-30 Janssen Sciences Ireland Unlimited Co Prueba de disolucion.
WO2023203258A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Liquid compositions
CN119403545A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
WO2023222755A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CN115490642B (zh) * 2022-09-21 2024-11-15 山东大学 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3953398A (en) * 1970-07-20 1976-04-27 The Goodyear Tire & Rubber Company Age resistant polymeric compositions
JPS63159316A (ja) * 1977-11-28 1988-07-02 アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド 中性銅結合体を含む抗炎症組成物
JPS5490121A (en) * 1977-11-28 1979-07-17 Boettcher Barry Neutral copper bonded body and antiinflaming agent
JPS5879920A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 血小板凝集阻害剤
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
SK67298A3 (en) 1995-11-23 1998-11-04 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP3990808B2 (ja) * 1998-03-26 2007-10-17 Ｔｄｋ株式会社 非水電解質電池用電極の製造方法
EP1245567B1 (en) 1998-03-27 2011-03-02 Janssen Pharmaceutica NV HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
JP2000035628A (ja) * 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
ATE342892T1 (de) * 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
CA2350801C (en) * 1998-11-10 2008-05-20 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
PT1159279E (pt) 1999-03-09 2003-02-28 Upjohn Co 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
KR100820605B1 (ko) * 1999-09-24 2008-04-08 얀센 파마슈티카 엔.브이. 항바이러스 조성물
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
HUP0303326A2 (hu) * 2001-03-02 2004-01-28 Smithkline Beecham Corporation Benzofenonszármazékok, mint reverz transzkriptáz inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2292753T4 (es) * 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003222310B2 (en) * 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN1747937A (zh) 2003-02-07 2006-03-15 詹森药业有限公司 预防hiv感染的嘧啶衍生物
US9226970B2 (en) * 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds

Also Published As

Publication number Publication date
LTPA2012008I1 (lt) 2012-06-25
US7125879B2 (en) 2006-10-24
HK1145449A1 (en) 2011-04-21
US9580392B2 (en) 2017-02-28
BE2012C020I2 (OSRAM) 2021-07-19
PL402388A1 (pl) 2013-04-02
KR20070101409A (ko) 2007-10-16
HRP20192051B1 (hr) 2022-05-27
HRP20192051A2 (hr) 2020-03-06
CY2012012I2 (el) 2015-08-05
LTC3808743I2 (OSRAM) 2023-04-25
CY2012013I1 (el) 2015-08-05
CN100509801C (zh) 2009-07-08
ES2799408T3 (es) 2020-12-17
EP3808743B1 (en) 2022-07-20
HU230192B1 (hu) 2015-09-28
NO2012010I1 (no) 2012-06-18
PL368270A1 (en) 2005-03-21
KR100969273B1 (ko) 2010-08-20
EP1419152A1 (en) 2004-05-19
DE122012000038I1 (de) 2012-09-20
FR12C0035I1 (OSRAM) 2012-06-22
BE2022C531I2 (OSRAM) 2022-08-09
LTC1419152I2 (lt) 2025-05-12
BR122015023612B8 (pt) 2021-05-25
CA2452217C (en) 2009-06-16
NO327639B1 (no) 2009-09-07
SI1419152T1 (sl) 2011-11-30
AU2002329238C1 (en) 2008-08-28
JP4838396B2 (ja) 2011-12-14
BR0211909A (pt) 2004-08-24
ES2923581T3 (es) 2022-09-28
JP2010077140A (ja) 2010-04-08
ZA200401159B (en) 2005-07-27
BRPI0211909B1 (pt) 2018-05-29
BR122015023612B1 (pt) 2021-01-19
JP2005507380A (ja) 2005-03-17
KR20040023645A (ko) 2004-03-18
HUP0401346A3 (en) 2009-03-02
MY189572A (en) 2022-02-17
LU92001I2 (fr) 2012-07-16
AU2002329238B2 (en) 2008-01-24
CY2012012I1 (el) 2015-08-05
NO20040633L (no) 2004-03-12
UA78221C2 (uk) 2007-03-15
CN1541215A (zh) 2004-10-27
KR100817453B1 (ko) 2008-03-27
FR22C1036I1 (fr) 2022-09-09
FR12C0036I2 (fr) 2016-05-06
HU231274B1 (hu) 2022-07-28
JP2011236221A (ja) 2011-11-24
EP2298761A1 (en) 2011-03-23
EP3808743A1 (en) 2021-04-21
US20170320835A1 (en) 2017-11-09
DK1419152T3 (da) 2011-10-24
JP5539927B2 (ja) 2014-07-02
JO3429B1 (ar) 2019-10-20
AR036387A1 (es) 2004-09-08
US20060252764A1 (en) 2006-11-09
CY2022024I1 (el) 2023-01-05
BRPI0211909B8 (pt) 2021-05-25
JP2011225589A (ja) 2011-11-10
HRP20120265B1 (hr) 2019-11-29
HRP20040096A2 (en) 2004-06-30
US20190322628A1 (en) 2019-10-24
IL160328A0 (en) 2004-07-25
BR122015032641B1 (pt) 2022-03-03
PA8552901A1 (es) 2003-02-28
SI3808743T1 (sl) 2022-09-30
US20040198739A1 (en) 2004-10-07
CA2452217A1 (en) 2003-02-27
AP2004002993A0 (en) 2004-03-31
US20120076835A1 (en) 2012-03-29
BE2012C022I2 (OSRAM) 2022-01-12
CY2022024I2 (el) 2023-01-05
US20170121292A1 (en) 2017-05-04
JP5247661B2 (ja) 2013-07-24
PL216398B1 (pl) 2014-03-31
FR12C0036I1 (OSRAM) 2012-06-29
HRP20040096B1 (hr) 2013-06-30
IL160328A (en) 2011-01-31
HUS1500055I1 (hu) 2016-03-29
LU92008I2 (fr) 2012-07-24
US20140343006A1 (en) 2014-11-20
CY2012013I2 (el) 2015-08-05
CY1112331T1 (el) 2015-08-05
US9981919B2 (en) 2018-05-29
EP1419152B1 (en) 2011-07-27
NO20083770L (no) 2004-03-12
NZ530951A (en) 2005-10-28
US8080551B2 (en) 2011-12-20
FR12C0035I2 (fr) 2016-02-12
US10370340B2 (en) 2019-08-06
EA006656B1 (ru) 2006-02-24
LTPA2022515I1 (OSRAM) 2022-08-25
HK1070066A1 (en) 2005-06-10
CN101816658A (zh) 2010-09-01
NO337142B1 (no) 2016-02-01
EG24684A (en) 2010-05-05
HUS2200038I1 (hu) 2022-08-28
US10611732B2 (en) 2020-04-07
MXPA04001401A (es) 2004-05-27
WO2003016306A1 (en) 2003-02-27
AP1610A (en) 2006-05-08
DK3808743T3 (da) 2022-08-01
LT3808743T (lt) 2022-08-10
CN101816658B (zh) 2014-08-27
PT1419152E (pt) 2011-10-11
OA12652A (en) 2006-06-15
HUS1500051I1 (hu) 2018-05-28
HUP0401346A2 (hu) 2004-12-28
ATE517891T1 (de) 2011-08-15
US20180244632A1 (en) 2018-08-30
NO2012010I2 (no) 2013-09-02
HRP20120265A2 (hr) 2012-05-31
EA200400304A1 (ru) 2004-08-26
EP2298761B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
ES2368996T3 (es) Derivados de pirimidinas inhibidores del hiv
ES2361835T3 (es) Derivados de purina inhibidores de la replicación del hiv.
ES2542326T3 (es) Inhibidores de la replicación del VIH
ES2371923T3 (es) 5-heterociclil-pirimidinas que inhiben el vih.
ES2371924T3 (es) Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv.
ES2311146T3 (es) 1,2,4-triazinas que inhiben el vih.
ES2290313T3 (es) Derivados de pirazinona que inhiben el vih.
ES2380631T3 (es) Pirimidinas sustituidas en posición 5 inhibidoras de VIH
ES2373820T3 (es) Derivados de 2-(4-cianofenilamino)pirimidina que inhiben el vih.
CN101133038B (zh) 抑制hiv的2-(4-氰基苯基)-6-羟氨基嘧啶
MX2007010051A (es) Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
ES2257081T3 (es) Derivados de 2,4-triazina disustituidos.
ES2365015T3 (es) Pirimidinas sustituidas con indano que inhiben la replicación del vih.
UA81292C2 (en) Hiv replication inhibiting pyrimidines and triazines